Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

Coupled with the fact that the automobile industry usually takes early vacations before the Spring Festival, the effective ...

Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

ET Net News Agency, 8 January 2025] A direct manual trade of 1.67 million shares of INNOVENT BIO (01801) was registered at 1:00p.m. The deal amounted to HK$56.6m, or at HK$33.8 p ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Key stocks recommended by Jefferies for 2025 include Mankind Pharma, JB Chemicals, and Sun Pharmaceutical Industries.

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Any differences are carefully ...

Nuvation Bio (NUVB) announced that China’s National Medical Products Administration or NMPA has approved taletrectinib for the treatment of ...

China’s National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of Dovbleron ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...